UT System ranked No. 3 nationally, No. 4 worldwide for U.S. utility patents

March 19, 2026

The University of Texas System ranked No. 4 in the National Academy of Inventors’ list of the Top 100 Worldwide Universities Granted U.S. Utility Patents in 2025. The system also ranked No. 3 in the Top 100 U.S. Universities list. Among the 229 patents secured by UT System institutions were 22 awarded to researchers from The University of Texas at San Antonio and its academic health center, UT Health San Antonio. The majority were related to healthcare.

Large rapamycin clinical trial launches at UT Health San Antonio

March 16, 2026

A drug once known almost exclusively for preventing organ transplant rejection is now at the center of a National Institute on Aging-funded clinical study at UT Health San Antonio, to determine how rapamycin should be used in older adults to promote healthy aging.

UT San Antonio advances in national Blue Ridge rankings

March 9, 2026

In its first appearance in the national standings as a united institution, UT San Antonio posted a strong performance in the latest rankings from the Blue Ridge Institute for Medical Research. The Blue Ridge Institute is an independent nonprofit organization that compiles annual funding data from the National Institutes of Health.

UT San Antonio to lead $38 million national trial testing drugs to extend healthspan

March 4, 2026

The Sam and Ann Barshop Institute for Longevity and Aging Studies at UT Health San Antonio, will receive up to $38 million to lead a national clinical trial funded by the Advanced Research Projects Agency for Health (ARPA-H), an agency of the U.S. Department of Health and Human Services.

Widely used metabolic drugs may help curb rising colorectal cancer in younger adults

March 2, 2026

A large, retrospective study conducted by scientists at The University of Texas at San Antonio suggests that people taking glucagon-like peptide-1 (GLP-1) receptor agonists — medications that are widely prescribed for metabolic disease — have a significantly lower risk of developing colorectal cancer compared with those taking aspirin.